Valuation: Evaxion A/S

Market Cap 26.27M 23.34M 21.86M 19.8M 37.33M 2.53B 37.64M 262M 102M 1.29B 98.61M 96.49M 4.16B P/E 2026 *
-78.8x
P/E 2027 * -210x
Enterprise Value 26.27M 23.34M 21.86M 19.8M 37.33M 2.53B 37.64M 262M 102M 1.29B 98.61M 96.49M 4.16B EV / Sales 2026 *
-
EV / Sales 2027 * 5.63x
Free-Float
58.26%
Yield 2026 *
-
Yield 2027 * -
1 day+0.32%
1 week-2.47%
Current month-3.66%
1 month+1.28%
3 months-7.33%
6 months-16.40%
Current year-33.75%
1 week 3.12
Extreme 3.12
3.35
1 month 3
Extreme 3
3.35
Current year 2.77
Extreme 2.77
5.48
1 year 2.77
Extreme 2.77
12.15
3 years 1.2
Extreme 1.2
68.05
5 years 1.2
Extreme 1.2
1,252
10 years 1.2
Extreme 1.2
1,252
Manager TitleAgeSince
Chief Executive Officer 59 23/11/2025
Corporate Officer/Principal 49 10/08/2008
Director of Finance/CFO 53 31/10/2024
Director TitleAgeSince
Chairman 58 24/11/2020
Director/Board Member 56 31/12/2017
Director/Board Member 68 24/05/2021
Date Insider Type Main position Quantity % Market Cap. Importance
16/04/26 Other

Director

2,376 0.0006%
18/03/26 Other

Chief Financial Officer

645,750 0.1549%
18/03/26 OtherCompany 360,406 0.0864%
Change 5-day change 1-year change 3-year change Capi.($)
+0.32%-2.47%-41.80%-92.82% 26.27M
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-0.93%+327.90%+691.25% 44.51B
-2.30%-4.06%+25.82%+31.42% 43.8B
+0.31%-1.15%+5.50%+112.56% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-3.38%-9.25%-12.85% 24.53B
Average +0.71%-0.46%+43.11%+103.76% 39.36B
Weighted average by Cap. +1.10%-0.50%+56.58%+134.19%

Financials

2026 *2027 *
Net sales - 4.67M 4.15M 3.89M 3.52M 6.64M 450M 6.69M 46.64M 18.13M 230M 17.53M 17.15M 739M
Net income -15.56M -13.82M -12.95M -11.73M -22.11M -1.5B -22.29M -155M -60.42M -765M -58.41M -57.15M -2.46B -11.81M -10.49M -9.83M -8.9M -16.79M -1.14B -16.92M -118M -45.87M -581M -44.34M -43.39M -1.87B
Net Debt - -
Projected Income Statement - Annual - Evaxion A/S
Logo Evaxion A/S
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Employees
46
Date Price Change Volume
06/10/26 US$3.180 +0.95% 35,873
05/10/26 US$3.150 -1.56% 38,242
02/10/26 US$3.200 +0.63% 33,920
01/10/26 US$3.180 -3.05% 38,121
30/09/26 US$3.280 +0.31% 18,053
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Evaxion A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.150USD
Average target price
11.25USD
Spread / Average Target
+257.14%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evaxion A/S
  1. Stock Market
  2. Stocks
  3. EVAX Stock